An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)

European Journal of Cancer

Volumn 43, Issue 11, 2007, Pages 1687-1693

  Aballea S ^a   Boler, A ^b   Craig, A ^c   Wasan, H ^d  

^a i3 Innovus   (United Kingdom)

^b Heron Evidence Development Ltd   (United Kingdom)

^c Sanofi aventis Ltd   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Chemotherapy; Colon cancer; Cost effectiveness; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; EVALUATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MONEY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 34447267474     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.05.001     Document Type: Article

References (23)

1. ISD Scotland National Statistics. Cancer incidence and mortality by site/type of cancer, sex and year of diagnosis/registration of death: 1994-2003; 2004. [cited 2006 Jun].
2. Northern Ireland Cancer Registry. Cancer incidence statistics; 2005. .
3. Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence 2003 report; 2004. [cited 2006 Jun].
4. National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2003, England. Series MB1 No. 34. Office for National Statistics, London; 2006.
5. CancerStats monograph 2004 - cancer incidence, survival and mortality in the UK and EU. Bowel cancer statistics. Cancer Research UK; 2004.
6. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004) 1797-1806
7. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350 (2004) 2343-2351
8. De GA, Boni C, Navarro M, et al. Oxaliplatin/5-FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. In: Proceedings ASCO-GI symposium; 2005. p. 167.
9. Wolmark N, Wiehand H, Kuebler JP. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. In: Proceedings of the ASCO Symposium; 2005 [Abs. LBA3500].
10. US Food and Drug Administration. Colorectal cancer endpoints workshop summary; 2004 November. [cited 2006 Jun].
11. Armitage P., Berry G., and Matthews J.N.S. Statistical methods in medical research. 4th ed. (2002), Blackwell Science, Oxford
12. Ramsey S.D., Andersen M.R., Etzioni R., et al. Quality of life in survivors of colorectal carcinoma. Cancer 88 (2000) 1294-1303
13. Health Survey for England 1996. The Stationery Office, London; 1996.
14. Cook J., Richardson J., and Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ 3 (1994) 157-168
15. Grunberg S.M., Srivastava A., Grunberg K.J., and Weeks J. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer 10 (2002) 624-629
16. Launois R., Reboul-Marty J., Henry B., and Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 10 (1996) 504-521
17. Department of Health. NHS reference costs 2003. In: National Health Service; ed. 2004.
18. Joint Formulary Committee. British national formulary (2004), British Medical Association and Royal Pharmaceutical Society of Great Britain, London
19. Aballea S., Chancellor J.V., Raikou M., et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109 (2007) 1082-1089
20. Aballea S, Chancellor J, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK and Germany. Value in Health; 2005 [Abs. CN1].
21. Cassidy J., Douillard J.Y., Twelves C., et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 94 (2006) 1122-1129
22. Devlin N., and Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13 (2004) 437-452
23. Schmoll HJ, Tabernero J, Nowacki M. Initial safety findings from XeloxA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. In: Proceedings of the 13th European Cancer Conference, Paris; 2005 [Abs. 617].